Furthermore, RPN13 knockdown by ADRM1 siRNA, or RA190 treatment causes loss of MM cell viability, including ex vivo patients’ samples and bortezomib-resistant lines, via caspase-dependent and UPR-related apoptosis [42]. Here, ADRM1 is linked to Miyoshi myopathy.